Neuroone Medical Valuation
| NMTC Stock | USD 0.83 0.06 6.74% |
Today, the firm appears to be overvalued. Neuroone Medical Tec secures a last-minute Real Value of $0.73 per share. The latest price of the firm is $0.83. Our model forecasts the value of Neuroone Medical Tec from analyzing the firm fundamentals such as Current Valuation of 37.57 M, profit margin of (0.81) %, and Return On Equity of -0.95 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Neuroone Medical's valuation include:
Price Book 6.2037 | Enterprise Value | Enterprise Value Ebitda (2.10) | Price Sales 3.7035 | Enterprise Value Revenue 4.1298 |
Overvalued
Today
Please note that Neuroone Medical's price fluctuation is abnormally volatile at this time. Calculation of the real value of Neuroone Medical Tec is based on 3 months time horizon. Increasing Neuroone Medical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Neuroone Medical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Neuroone Stock. However, Neuroone Medical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.83 | Real 0.73 | Target 2.23 | Hype 0.83 | Naive 0.82 |
The real value of Neuroone Stock, also known as its intrinsic value, is the underlying worth of Neuroone Medical Tec Company, which is reflected in its stock price. It is based on Neuroone Medical's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Neuroone Medical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Neuroone Medical Technologies helps investors to forecast how Neuroone stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Neuroone Medical more accurately as focusing exclusively on Neuroone Medical's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Neuroone Medical's intrinsic value based on its ongoing forecasts of Neuroone Medical's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Neuroone Medical's closest peers. If more than one evaluation category is relevant for Neuroone Medical we suggest using both methods to arrive at a better estimate.
Neuroone Medical Cash |
|
Neuroone Medical Total Value Analysis
Neuroone Medical Technologies is now anticipated to have valuation of 37.57 M with market capitalization of 33.89 M, debt of 266.81 K, and cash on hands of 10.18 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Neuroone Medical fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
37.57 M | 33.89 M | 266.81 K | 10.18 M |
Neuroone Medical Investor Information
About 35.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.16. Neuroone Medical Tec had not issued any dividends in recent years. The entity had 1:3 split on the 1st of April 2021. Neuroone Medical Technologies may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.Neuroone Medical Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Neuroone Medical has an asset utilization ratio of 112.16 percent. This indicates that the Company is making $1.12 for each dollar of assets. An increasing asset utilization means that Neuroone Medical Technologies is more efficient with each dollar of assets it utilizes for everyday operations.Neuroone Medical Profitability Analysis
Taking into consideration Neuroone Medical's profitability measurements, Neuroone Medical's profitability may be sliding down. It has an above-average probability of reporting lower numbers next quarter. Profitability indicators assess Neuroone Medical's ability to earn profits and add value for shareholders.Net Loss | First Reported 2010-06-30 | Previous Quarter -1.5 M | Current Value -1.6 M | Quarterly Volatility 1.5 M |
For Neuroone Medical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Neuroone Medical Tec to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Neuroone Medical utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Neuroone Medical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Neuroone Medical over time as well as its relative position and ranking within its peers.
Neuroone Medical Earnings per Share Projection vs Actual
By analyzing Neuroone Medical's earnings estimates, investors can diagnose different trends across Neuroone Medical's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Neuroone Medical Technologies is based on EPS before non-recurring items and includes expenses related to employee stock options.Neuroone Medical Ownership Allocation
Neuroone Medical Tec maintains a total of 50 Million outstanding shares. 30% of Neuroone Medical outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Neuroone Medical Profitability Analysis
The company reported the previous year's revenue of 12.1 M. Net Loss for the year was (3.61 M) with loss before overhead, payroll, taxes, and interest of (1.23 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Neuroone Medical's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Neuroone Medical and how it compares across the competition.
About Neuroone Medical Valuation
The stock valuation mechanism determines Neuroone Medical's current worth on a weekly basis. Our valuation model uses a comparative analysis of Neuroone Medical. We calculate exposure to Neuroone Medical's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Neuroone Medical's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 9.4 M | 9.8 M | |
| Pretax Profit Margin | (41.66) | (43.75) | |
| Operating Profit Margin | (41.66) | (43.75) | |
| Net Loss | (84.72) | (80.48) | |
| Gross Profit Margin | 0.60 | 0.63 |
Neuroone Medical Current Valuation Indicators
Valuation refers to the process of determining the present value of Neuroone Medical Technologies and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Neuroone we look at many different elements of the entity such as Neuroone's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Neuroone Medical, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Neuroone Medical's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Neuroone Medical's worth.Complementary Tools for Neuroone Stock analysis
When running Neuroone Medical's price analysis, check to measure Neuroone Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuroone Medical is operating at the current time. Most of Neuroone Medical's value examination focuses on studying past and present price action to predict the probability of Neuroone Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuroone Medical's price. Additionally, you may evaluate how the addition of Neuroone Medical to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Stocks Directory Find actively traded stocks across global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |